Comparison of post‐transplant cyclophosphamide and low‐dose anti‐thymocyte globulin with dose‐dependent effects in mismatched unrelated donor transplantation

Q: What does this research mean for the field?

In mismatched unrelated donor transplantation, post-transplant cyclophosphamide is associated with a significantly lower risk of acute GVHD compared to low-dose anti-thymocyte globulin, while higher doses of ATG (>2.5 mg/kg) provide comparable protection against chronic GVHD with no significant differences in overall survival. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

Masatomo Kuno; Hirohisa Nakamae; Koji Kawamura; Shunto Kawamura; Takahiro Fukuda; Yuta Katayama; Yoshinobu Kanda; Noriko Doki; Hideyuki Nakazawa; Kentaro Fukushima; Toshihiro Matsukawa; Jun Ishikawa; Masashi Sawa; Takashi Ikeda; Kazunori Imada; Katsuhiro Shono; Yoshiko Atsuta; Hideki Nakasone; the Donor/Source Working Group of the Japan Society for Transplantation and Cellular Therapy

doi:10.1111/bjh.70791

Key Points

To compare clinical outcomes between post-transplant cyclophosphamide and low-dose anti-thymocyte globulin while evaluating the dose-dependent effects of anti-thymocyte globulin in mismatched unrelated donor stem cell transplantation.
Nationwide registry analysis of 1228 adult patients undergoing HLA-mismatched unrelated donor transplantation for hematological malignancies in Japan between 2015 and 2022 (PTCY, n = 53; ATG, n = 1175).
ATG recipients were categorized by dose (<2.0 mg/kg, n = 262; 2.0–2.5 mg/kg, n = 706; >2.5 mg/kg, n = 74) and compared against PTCY (median dose 100 mg/kg) using multivariable and propensity score-matched analyses.
All ATG dose groups were associated with a significantly higher risk of grade II–IV and grade III–IV acute graft-versus-host disease compared with the PTCY cohort.
One-year cumulative incidence of chronic graft-versus-host disease showed a dose-dependent reduction across ATG groups: 34% (<2.0 mg/kg), 25% (2.0–2.5 mg/kg), and 15% (>2.5 mg/kg), compared to 16% with PTCY (p < 0.001).
No significant differences were detected among the treatment groups for relapse, non-relapse mortality, graft-versus-host disease-free relapse-free survival, or overall survival.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Cohort study demonstrates lower acute graft-versus-host disease with post-transplant cyclophosphamide versus anti-thymocyte globulin in mismatched donor transplants, indicating superior protection.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kuno et al. (2026) studied this question.

synapsesocial.com/papers/6a93f00a6c1a8fb52e79c144 https://doi.org/10.1111/bjh.70791

View Full Paper

Ask AI

Bookmark

Share

Comparison of post‐transplant cyclophosphamide and low‐dose anti‐thymocyte globulin with dose‐dependent effects in mismatched unrelated donor transplantation

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Comparison of post‐transplant cyclophosphamide and low‐dose anti‐thymocyte globulin with dose‐dependent effects in mismatched unrelated donor transplantation

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

More related papers

More from British Journal of Haematology

Keep reading

More related papers

More from British Journal of Haematology